Miracle Mile Advisors LLC Makes New $272,000 Investment in Zoetis Inc. (NYSE:ZTS)

Miracle Mile Advisors LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,670 shares of the company's stock, valued at approximately $272,000.

A number of other institutional investors have also modified their holdings of the business. Darwin Wealth Management LLC purchased a new position in shares of Zoetis in the 3rd quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis in the third quarter valued at $33,000. Capital Performance Advisors LLP purchased a new position in Zoetis during the 3rd quarter valued at about $33,000. Dunhill Financial LLC raised its position in shares of Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company's stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP raised its holdings in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after acquiring an additional 153 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

NYSE:ZTS traded down $3.36 during trading hours on Friday, hitting $166.01. 4,656,391 shares of the company traded hands, compared to its average volume of 2,867,942. The firm has a 50-day moving average of $171.15 and a 200 day moving average of $179.99. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market capitalization of $74.90 billion, a price-to-earnings ratio of 31.20, a P/E/G ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm's revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.36 earnings per share. On average, analysts forecast that Zoetis Inc. will post 5.91 EPS for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. This is a boost from Zoetis's previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. Zoetis's dividend payout ratio (DPR) is currently 37.59%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price objective on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price on the stock. Leerink Partnrs upgraded Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, Leerink Partners initiated coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price for the company. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of "Buy" and an average price target of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.